FDA Approves Synergy Disc, Expanding Options for Cervical Spine Replacement
The US Food and Drug Administration (FDA) has granted premarket approval (PMA) to Synergy Spine Solutions for its Synergy Disc, a novel artificial disc designed for cervical disc replacement. This approval marks a significant advancement in the treatment of degenerative disc disease, offering patients a motion-preserving alternative to traditional spinal fusion surgery. The decision follows compelling clinical evidence demonstrating the Synergy Disc’s superiority to fusion in achieving positive clinical outcomes, potentially improving the quality of life for individuals suffering from debilitating neck pain.
Degenerative disc disease affects millions worldwide, causing chronic pain, limited range of motion, and neurological symptoms. Traditional treatment often involves spinal fusion, a procedure that eliminates motion between vertebrae. While effective in stabilizing the spine, fusion can sometimes lead to adjacent segment disease, where increased stress is placed on the discs above and below the fused area, potentially requiring further surgery. The Synergy Disc aims to address these limitations by preserving natural spinal motion and alignment, offering a more biomechanically sound solution for select patients.
Clinical Trial Results Demonstrate Superiority
The FDA’s approval is based on data from a prospective, investigational device exemption (IDE) clinical study conducted in the United States. Results published at the 24-month mark revealed a composite clinical success rate of 87.1% for patients receiving the Synergy Disc. This outcome was significantly higher than the 75.2% success rate observed in the fusion group. Clinical success was defined by a composite of factors including pain relief, functional improvement, and absence of re-operation.
Beyond the overall success rate, patients treated with the Synergy Disc experienced substantial improvements in pain and disability. Specifically, 91.7% of Synergy Disc recipients reported clinically meaningful improvement on the Neck Disability Index (NDI) at two years, compared to 75.2% in the fusion group. The NDI is a widely used questionnaire assessing the impact of neck pain on daily activities. The average neck pain score for Synergy Disc patients was 15.6, considerably lower than the 30.2 score reported by those who underwent fusion. Patients also reported significantly less arm pain, with an average worst arm pain score of 15.0 compared to 32.2 in the fusion group. These findings, published by Synergy Spine Solutions, suggest a substantial reduction in both neck and radiating arm pain with the Synergy Disc.
The study also demonstrated improvements in spinal alignment. The disc angle increased from an average of 2.6° pre-operatively to 6.5° at 24 months post-surgery. This restoration of natural lordosis, the inward curve of the cervical spine, is believed to contribute to improved biomechanics and reduced stress on surrounding structures. Importantly, overall patient satisfaction was also higher in the Synergy Disc group, with 84.5% reporting satisfaction compared to 61.6% in the fusion group.
Synergy Disc: A Unique Approach to Cervical Disc Replacement
The Synergy Disc distinguishes itself from other artificial discs through its unique design, which incorporates a lordotic core. According to Synergy Spine Solutions CEO Josh Butters, this feature allows the disc to not only preserve motion but also correct focal spinal alignment. “FDA approval of the Synergy Disc marks a pivotal moment – bringing US surgeons and patients the first motion-preserving disc that also corrects focal spinal alignment with its unique lordotic core,” Butters stated. “We are thrilled with the clinical outcomes achieved in this study, and this approval reflects years of focused development, clinical evaluation, and surgeon-led innovation aimed at solving persistent challenges in cervical disc replacement.”
The Synergy Disc is indicated for use in single-level cervical disc replacement at vertebral levels C3-C7. This means We see designed to replace a damaged disc at one level of the neck. The device is intended for patients diagnosed with degenerative disc disease, a condition characterized by the breakdown of the intervertebral discs, leading to pain, stiffness, and neurological symptoms. The FDA approval specifically covers its use in patients with this condition who have not responded adequately to conservative treatments such as physical therapy and pain medication.
Commercialization and Future Studies
Synergy Spine Solutions plans to begin commercializing the Synergy Disc in the United States in early 2026. This will involve training surgeons on the proper implantation techniques and establishing a distribution network to build the device available to patients across the country. The company anticipates a phased rollout, starting with centers specializing in spinal surgery and gradually expanding to broader adoption.
In addition to the approved indication for single-level replacement, Synergy Spine Solutions is currently conducting an IDE study to evaluate the Synergy Disc for use in two-level cervical disc replacement. This trial is fully enrolled, and two-year follow-up data is expected later in 2026. Successful completion of this study could further expand the applicability of the Synergy Disc, offering a solution for patients with more extensive degenerative disc disease. The company secured $30 million in Series A funding in 2024 to support these clinical trials and regulatory efforts, as reported by Medical Device Network.
The Future of Cervical Spine Surgery
The approval of the Synergy Disc represents a significant step forward in the field of cervical spine surgery. By offering a motion-preserving alternative to fusion, the device has the potential to improve patient outcomes, reduce the risk of adjacent segment disease, and enhance overall quality of life. As the Synergy Disc becomes more widely available, it is likely to become a valuable tool for surgeons treating patients with degenerative disc disease. The ongoing study evaluating its use in two-level replacements will further refine its role in the treatment landscape.
The development of innovative technologies like the Synergy Disc underscores the ongoing commitment to improving the care of patients with spinal disorders. Continued research and development in this area are crucial to addressing the challenges posed by degenerative disc disease and providing patients with the most effective and least invasive treatment options available.
Next Steps: Synergy Spine Solutions anticipates publishing further data from the ongoing two-level IDE study later in 2026. Patients interested in learning more about the Synergy Disc are encouraged to discuss it with their spine surgeon to determine if it is an appropriate treatment option.
Do you have experience with cervical disc replacement surgery? Share your thoughts and questions in the comments below.